LIVERFASt™

Fibrosis • Activity • Steatosis



An innovative diagnostic and screening tool for a

COMPLETE LIVER EVALUATION

unicus med

LIVERFASt™ Provides a Full Liver Evaluation for Multiple Etiologies

Non-Alcoholic Fatty Liver Disease (NAFLD)

25% of the US population have NAFLD[3]

30% of NAFLD patients will develop Non-Alcoholic Steatohepatitis (NASH)

Hepatitis B (HBV)

20% -30% of patients with chronic HBV infection will develop cirrhosis or liver cancer[1]

Hepatitis C (HCV)

15% -30% of patients with chronic HCV infection will suffer from cirrhosis[2]

Alcoholic Liver Disease (ALD)

48% of all deaths from cirrhosis are caused by ALD[4]

S-A-F Score Staging6

Fibrosis

SCORE	STAGE	INTERPRETATION
0.00 - 0.27	F0	No fibrosis
0.28 - 0.48	F1	Mild fibrosis
0.49 - 0.58	F2	Advanced fibrosis
0.59 - 0.74	F3	Significant fibrosis
0.75 - 1.00	F4	Severe fibrosis (cirrhosis)

Activity

SCORE	GRADE	INTERPRETATION
0.00 - 0.29	A0	No activity
0.30 - 0.52	A1	Mild activity
0.53 - 0.62	A2	Moderate activity
0.63 - 0.72	A3	Marked activity
0.73 - 1.00	A4	Severe activity

Steatosis

SCORE	STAGE	INTERPRETATION
0.00 - 0.37	S0	No steatosis (<5%)
0.38 - 0.56	S1	Mild steatosis (5-33%)
0.57 - 0.68	S2	Moderate steatosis (34-66%)
0.69 - 1.00	S3	Marked steatosis (>67%)

Distinctive Staging of Three Lesions

LIVERFASt™ provides a complete liver evaluation with the staging of fibrosis, activity, and steatosis.

	Specific for **Fibrosis (F)**	Specific for **Activity (A)**	Specific for **Steatosis (S)**	**NASH** Staging	No. of **Biomarkers**	Assessment **Unbiased towards fibrosis**
LIVERFASt™	✔	✔	✔	✔	10	✔
Fibroscan	✔ (BMI-impacted cutoffs)	✖	✔	✔ Only severe NASH	US	✖ (A,S)

Simple and Convenient with Immediate Results

Physician prescribes **LIVERFASt™** for the patient

Lab analyses 10 biomarkers from **1 blood sample**

Biomarker results and **patient specific characteristics** input into Fibronostics' proprietary Artificial Intelligence (AI) platform

LIVERFASt™ results are **available immediately**

LIVERFASt™ in non-alcoholic fatty liver (NAFLD) patients[6,8-9,14]

LIVERFASt™ Fibrosis score accurately detects cirrhosis, AUROC (95%), in NAFLD patients, with or without type 2 diabetes mellitus (T2DM) and provides results similar to transient elastography (TE), P=NS.9

Patients without T2DM	0.824 (.737 - .888), p=NS versus TE
Patients with T2DM	0.774 (.722 - .839), p = NS versus TE



LIVERFASt™ identifies NASH even in subjects with normal liver enzymes.

LIVERFASt™ Steatosis score outperforms ultrasound in the detection of moderate steatosis (Grades S2S3, >33% of hepatocytes) in obese patients and CAP for obese patients with BMI>35Kg/m2 and T2Diabetes.9

LIVERFASt™ improves the identification of NASH and demonstrates superior performance to FIB-4.

AUROC (95% CI) for all stages of NASH	
LIVERFASt	0.88 (0.75 - 0.94)
FIB-4	0.68 (0.54 - 0.77), p<0.0019

> Look for NAFLD in patients with Type 2 Diabetes Mellitus, irrespective of liver enzyme levels, due to high risk of disease progression.[14]
>
> EASL, 2016

> **Patients with type 2 diabetes or prediabetes and elevated liver enzymes (ALT) or fatty liver on ultrasound should be evaluated for presence of nonalcoholic steatohepatitis and liver fibrosis. […] Noninvasive tests, such as fibrosis biomarkers, may be used to assess risk of fibrosis »** [15]
>
> American Diabetes Association, 2021

25%
of people with Metabolic Syndrome risk factors* have non-alcoholic fatty liver disease (NAFLD).
Prevalence of NAFLD in patients with Type 2 Diabetes is two times higher than in the general population.

30%
of people with fat droplets in their liver cells develop non-alcoholic steatohepatitis (NASH), where the liver becomes inflamed and the hepatocytes suffer from ballooning.[3,13]

20%
of people with NASH will develop scarring (fibrosis) of the liver and the hepatocytes suffer from ballooning.[3,14]



Healthy Liver — **Simple Fatty Liver** — **Fatty Liver with Inflammation /Scarring** — **Liver Cirrhosis**

FIBRONOSTICS **LIVERFASt™**

SAMPLE RESULT SHEET

Test id: 45843
Reference no: GLI021031108907

PATIENT NAME:	PHYSICIAN NAME:
	JOHN DOE M.D., P.A.

DATE OF BIRTH:	GENDER:	HEIGHT:	WEIGHT:	BMI:	DATE TEST TAKEN:
25-08-1964	Female	1.66 m	76kg	27.6	15-04-2021

TEST SCORES



Fibrosis	Activity	Steatosis
0.77 Stage F4 Severe Fibrosis/Cirrhosis	0.76 Grade A4 Severe Activity	0.84 Grade S3 Marked Steatosis

INTERPRETATION

The result as per the SAF (Steatosis Activity Fibrosis) histological score is estimated at S3-A4-F4. This score indicates severe fibrosis/cirrhosis, severe activity, and marked steatosis.

BIOMARKER RESULTS

AGE: 56 years old GENDER: Female BODY MASS INDEX: 27.6

Sample Date: March 12,2021

	Result	Unit		Result	Unit
alpha-2-Macroglobulin	2.9	g/L	ALT	105	IU/L
Haptoglobin	0.7	g/L	AST	91	mg/dL
Apolipoprotein A1	1.17	g/L	Fasting Glucose	5.8	mmol/L
Total Bilirubin	12.5	µmol/L	Total Cholesterol	5.5	mmol/L
GGT	211	IU/L	Triglycerides	1.5	mmol/L

*Warning: This value is out of the 98% range. Check this value.

CLIA# 10D2190357
This report is computer generated. No signature required.

AMA CE

UNICUS MARKETING MANAGEMENT LLC

FIBRONOSTICS

Fibronostics specializes in algorithm-based noninvasive diagnostic solutions.

For more information, please visit **www.fibronostics.com**

Contact Us
For business enquiries: **info@unicusmed.com**
For medical and scientific enquiries: **service@fibronostics.com**

References:
1. "Hepatitis B." World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
2. "Hepatitis C." World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
3. Younossi, Z. M. et al. "Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes." Hepatology. 2016; 64: 73–84
4. Liangpunsakul, S. et al. "Alcoholic Liver Disease in Asia, Europe, and North America." Gastroenterology. 2016; 150: 1786-1797
5. Bedossa, P, et al. L. Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 6: 5-8.
6. Bedossa P, et al. Histopathological algorithm and scoring system for evaluation of liver lesions tin morbidly obese patients. Hepatology. 2012;56(5):1751-1759.
7. Jung, E.S., et al. (2016), Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease. Journal of pathology and translational medicine, 50(3): 190–196. doi:10.4132/jptm.2016.03.01jptm-2016-03-01
8. Aravind A ,et al. Machine Learning Technology for Evaluation of Liver Fibrosis, Inflammation Activity and Steatosis (LIVERFASt™) JILSA 2020, 12, 31-49.
9. deLedinghen V. et al. Comparative performances of Liverfast, VCTE(Fibroscan), and others erum non-invasive tests (NITs) for the diagnosis of advanced chronic liver diseases in NAFLD from a cohort with liver biopsy. Submitted to Hepatology 2020
10.Tangvoraphonkchai K., et al. Comparative assessment liver lesions using non-invasive serum biomarkers Liverfast, FIB4, APRI and liver stiffness measurement (LSM, Fibroscan) in chronic hepatitis C (CHC) patients with liver biopsy. Journal of the Medical Association of Thailand in press.
11. Lim S.G., et al. Predictive value of non-invasive methods liverfast, acoustic radiation force impulse (ARFI), FIB-4 and APRI to identify the natural phases of chronic hepatitis B (CHB) infection from the National University Hospital (NUH) CHB study cohort of Singapore. Submitted to AASLD Liver Meeting 2020
12. 1. "Liver Issues That Should Not Be Ignored." Star2.com, https://www.star2.com/health/2018/08/19/liver-issues-not-ignored/
13. Sarah, D. "Disease progression: Divergent paths." Nature. 2017 November; 551: S92-S93
14. European Association for the Study of the Liver (EASL). "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease." Journal of Hepatology. 2016 June; 64(6):1388-402
15. American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021 Jan; 44(Supplement 1): S40-S5